Skip to search formSkip to main contentSkip to account menu

eluxadoline

Known as: 5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
2019
2019
OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder with limited effective… 
Review
2018
Review
2018
  • B. Lacy
  • Alimentary pharmacology & therapeutics
  • 2018
  • Corpus ID: 52174948
Irritable bowel syndrome (IBS) is multifactorial in nature, and a wide range of therapies is available to manage symptoms of this… 
Highly Cited
2017
Highly Cited
2017
Objectives:Eluxadoline is a mixed μ-opioid receptor (OR) and κ-OR agonist and δ-OR antagonist, approved for the treatment of… 
2017
2017
Objectives:Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide… 
Review
2017
Review
2017
This review introduces the principles of visceral sensation and appraises the current approaches to management of visceral pain… 
Review
2017
Review
2017
Highly Cited
2016
Highly Cited
2016
Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We… 
2015
2015
The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist… 
Highly Cited
2013
Highly Cited
2013
BACKGROUND & AIMS Simultaneous agonism of the μ-opioid receptor and antagonism of the δ-opioid receptor can reduce abdominal pain…